FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765222635> ?p ?o ?g. }

• W2765222635 abstract "Background: Intravesical Bacillus Calmette-Guerin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer(NMIBC) following transurethral resection, however BCG failure and related toxicities are common. Objectives: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. Methods: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015. The survival cut off was December 2016. Primary end point was disease free survival (DFS) and secondary end point was toxicity. After optimal transurethral resection all patients received weekly intravesical BCG or gemcitabine for 6 weeks and maintenance treatment according to their risk. The recurrence was defined as histology proven tumour recurrence (any grade), or appearance of CIS. Results: One hundred and three patients were evaluable, 52 treated with BCG and 51 with gemcitabine with a median age of 77 and 78, and were mostly male. Approximately half of each received maintenance therapy. The groups were well balanced, apart from some difference in cancer risk groups. Twenty-one percent in the BCG group and 29% in the gemcitabine group had received prior BCG. Median follow up was 15.0 months. Median DFS was 19.6 months for BCG, whereas median DFS was not reached with gemcitabine. There was a trend towards improved DFS with gemcitabine in multivariate analysis, HR: 0.49 (95% CI: 0.22 – 1.06, p = 0.07). Adverse events were significantly less frequent with gemcitabine (7% v 44%, p=<0.05). There were 4 cases of systemic BCG infection. Conclusion: Intravesical gemcitabine was associated with a trend towards better DFS with significantly lower toxicity when compared with BCG. Intravesical gemcitabine could be a reasonable alternative to BCG in cases where BCG is contraindicated and for patients who are intolerant or refractory to BCG.A prospective phase 3 trial is needed to confirm the benefits of gemcitabine over BCG." @default.
• W2765222635 created "2017-11-10" @default.
• W2765222635 creator A5003198373 @default.
• W2765222635 creator A5003227977 @default.
• W2765222635 creator A5028963575 @default.
• W2765222635 creator A5042081531 @default.
• W2765222635 creator A5055106803 @default.
• W2765222635 date "2017-11-02" @default.
• W2765222635 modified "2023-10-17" @default.
• W2765222635 title "Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity" @default.
• W2765222635 cites W1488187260 @default.
• W2765222635 cites W1586356187 @default.
• W2765222635 cites W1692007494 @default.
• W2765222635 cites W1745385465 @default.
• W2765222635 cites W1981349516 @default.
• W2765222635 cites W1987030333 @default.
• W2765222635 cites W1987652810 @default.
• W2765222635 cites W2039218197 @default.
• W2765222635 cites W2042179480 @default.
• W2765222635 cites W2050738164 @default.
• W2765222635 cites W2077884368 @default.
• W2765222635 cites W2107944116 @default.
• W2765222635 cites W2147633207 @default.
• W2765222635 cites W2151781453 @default.
• W2765222635 cites W2162443933 @default.
• W2765222635 cites W2162756611 @default.
• W2765222635 cites W2165562791 @default.
• W2765222635 cites W2417005903 @default.
• W2765222635 cites W2752261419 @default.
• W2765222635 cites W4233621581 @default.
• W2765222635 cites W4242323062 @default.
• W2765222635 cites W4251083747 @default.
• W2765222635 cites W4295773318 @default.
• W2765222635 doi "https://doi.org/10.3389/fonc.2017.00260" @default.
• W2765222635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5673621" @default.
• W2765222635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29164059" @default.
• W2765222635 hasPublicationYear "2017" @default.
• W2765222635 type Work @default.
• W2765222635 sameAs 2765222635 @default.
• W2765222635 citedByCount "25" @default.
• W2765222635 countsByYear W27652226352018 @default.
• W2765222635 countsByYear W27652226352019 @default.
• W2765222635 countsByYear W27652226352020 @default.
• W2765222635 countsByYear W27652226352021 @default.
• W2765222635 countsByYear W27652226352022 @default.
• W2765222635 countsByYear W27652226352023 @default.
• W2765222635 crossrefType "journal-article" @default.
• W2765222635 hasAuthorship W2765222635A5003198373 @default.
• W2765222635 hasAuthorship W2765222635A5003227977 @default.
• W2765222635 hasAuthorship W2765222635A5028963575 @default.
• W2765222635 hasAuthorship W2765222635A5042081531 @default.
• W2765222635 hasAuthorship W2765222635A5055106803 @default.
• W2765222635 hasBestOaLocation W27652226351 @default.
• W2765222635 hasConcept C121608353 @default.
• W2765222635 hasConcept C126322002 @default.
• W2765222635 hasConcept C126894567 @default.
• W2765222635 hasConcept C141071460 @default.
• W2765222635 hasConcept C168563851 @default.
• W2765222635 hasConcept C197934379 @default.
• W2765222635 hasConcept C203092338 @default.
• W2765222635 hasConcept C2777844706 @default.
• W2765222635 hasConcept C2777863537 @default.
• W2765222635 hasConcept C2780258809 @default.
• W2765222635 hasConcept C2780352672 @default.
• W2765222635 hasConcept C29730261 @default.
• W2765222635 hasConcept C71924100 @default.
• W2765222635 hasConceptScore W2765222635C121608353 @default.
• W2765222635 hasConceptScore W2765222635C126322002 @default.
• W2765222635 hasConceptScore W2765222635C126894567 @default.
• W2765222635 hasConceptScore W2765222635C141071460 @default.
• W2765222635 hasConceptScore W2765222635C168563851 @default.
• W2765222635 hasConceptScore W2765222635C197934379 @default.
• W2765222635 hasConceptScore W2765222635C203092338 @default.
• W2765222635 hasConceptScore W2765222635C2777844706 @default.
• W2765222635 hasConceptScore W2765222635C2777863537 @default.
• W2765222635 hasConceptScore W2765222635C2780258809 @default.
• W2765222635 hasConceptScore W2765222635C2780352672 @default.
• W2765222635 hasConceptScore W2765222635C29730261 @default.
• W2765222635 hasConceptScore W2765222635C71924100 @default.
• W2765222635 hasLocation W27652226351 @default.
• W2765222635 hasLocation W27652226352 @default.
• W2765222635 hasLocation W27652226353 @default.
• W2765222635 hasLocation W27652226354 @default.
• W2765222635 hasLocation W27652226355 @default.
• W2765222635 hasOpenAccess W2765222635 @default.
• W2765222635 hasPrimaryLocation W27652226351 @default.
• W2765222635 hasRelatedWork W1930516194 @default.
• W2765222635 hasRelatedWork W1974995659 @default.
• W2765222635 hasRelatedWork W2047788442 @default.
• W2765222635 hasRelatedWork W2055810949 @default.
• W2765222635 hasRelatedWork W2132919001 @default.
• W2765222635 hasRelatedWork W2132958436 @default.
• W2765222635 hasRelatedWork W2156576546 @default.
• W2765222635 hasRelatedWork W2343453515 @default.
• W2765222635 hasRelatedWork W3149052091 @default.
• W2765222635 hasRelatedWork W4361824915 @default.
• W2765222635 hasVolume "7" @default.
• W2765222635 isParatext "false" @default.
• W2765222635 isRetracted "false" @default.
• W2765222635 magId "2765222635" @default.

• next